Earnings Call Summary | MaxCyte(MXCT.US) Q4 2023 Earnings Conference
Earnings Call Summary | MaxCyte(MXCT.US) Q4 2023 Earnings Conference
The following is a summary of the MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript:
以下是MaxCyte, Inc.（MXCT）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
MaxCyte reported a full year revenue of $41.3 million in 2023, down 7% from 2022. However, Q4 2023 revenue increased by 26% to $15.7 million, compared to Q4 2022.
Their Q4 2023 core revenue was down by 32% at $7.2 million due to a decline in revenue from cell therapy and drug discovery customers.
Gross margin for Q4 2023 was at 90%, an increase from 88% in Q4 2022.
The company closed the year with an impressive $211 million in cash and no outstanding debt.
The company's SPL program-related revenue experienced significant growth in Q4 2023, making $8.5 million as opposed to $1.9 million in Q4 2022.
MaxCyte報告稱，2023年全年收入爲4,130萬美元，比2022年下降7％。但是，與2022年第四季度相比，2023年第四季度的收入增長了26％，達到1,570萬美元。
由於細胞療法和藥物發現客戶的收入下降，他們的2023年第四季度核心收入下降了32％，至720萬美元。
2023年第四季度的毛利率爲90％，高於2022年第四季度的88％。
該公司以令人印象深刻的2.11億美元現金結束了年底，沒有未償債務。
該公司的SPL計劃相關收入在2023年第四季度實現了顯著增長，收入爲850萬美元，而2022年第四季度爲190萬美元。
Business Progress:
業務進展：
MaxCyte's ExPERT platform became the only electroporation platform to have supported a non-viral therapy through FDA approval in 2023.
The company managed to expand its instrument installed base from 616 in 2022 to 683 in 2023.
MaxCyte signed 5 new Strategic Platform License Agreements (SPLs) in 2023, taking the total to 23 at the end of the year. This subsequently increased to 26 contracts in 2024.
As part of their 2024 strategic plan, MaxCyte aims to enhance its electroporation system to sell into new applications for electroporation.
The company is currently developing the VLx technology, which is expected to enable rapid production of transiently expressed proteins for preclinical and early clinical use.
2023年，MaxCyte的專家平台成爲唯一一個通過美國食品藥品管理局批准支持非病毒療法的電穿孔平台。
該公司設法將其儀器安裝量從2022年的616臺擴大到2023年的683臺。
MaxCyte在2023年簽署了5份新的戰略平台許可協議（SPL），使年底的總數達到23份。隨後，這一數字在2024年增加到26份合約。
作爲其2024年戰略計劃的一部分，MaxCyte旨在增強其電穿孔系統，以銷售到新的電穿孔應用。
該公司目前正在開發vLx技術，預計該技術將能夠快速生產用於臨床前和早期臨床用途的瞬時表達蛋白。
More details: MaxCyte IR
更多詳情： maxCyte 紅外
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。